OnBioVC

Otonomy, Inc.: Series B $38.5M

arubenstein — Thu, 02 Sep 2010 05:41:42 +0000

Otonomy (San Diego, CA) a clinical-stage biopharmaceutical company focused on, hearing and balance disorders such as Ménière’s disease, hearing loss, and tinnitus. closed a $38.5M Series B financing. Participants include Novo Ventures, RiverVest Venture Partners, Domain Associates and TPG Biotech.

Aptus Endosystems, Inc.: Series D $15

arubenstein — Wed, 01 Sep 2010 04:35:01 +0000

Aptus Endosystems (Sunnyvale, CA) a clinical-stage medical device company focused on endovascular aneurysm repair, closed a $15M Series D financing. Participants include US Venture Partners and Longitude Capital.

EndoGastric Solutions, Inc.: Series F $30M

arubenstein — Tue, 31 Aug 2010 04:54:58 +0000

EndoGastric Solutions (Redmond, WA) a commercial-stage medical device company focused on endoluminal procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease (GERD) and other GI disorders, closed a $30M Series F financing. Participants have included Canaan Partners, Radius Ventures, Advanced Technology Ventures, Chicago Growth Partners, DeNovo Ventures, Foundation Medical Partners, MPM Capitaland Oakwood Medical Investors.

Si-Bone, Inc.: Series B $10.6M

arubenstein — Mon, 30 Aug 2010 04:10:02 +0000

Si-Bone (San Jose, CA) a commercial-stage medical device company focused on minimally-invasive approaches to sacroiliac joint disruptions and degenerative sacroiliitis, closed a $10.6M Series B. Participants include Skyline Ventures.

Complete Genomics, Inc.: Series E $39M

arubenstein — Fri, 27 Aug 2010 05:29:39 +0000

Complete Genomics (Mountain View, CA) a commercial-stage sequencing company building a human genome sequencing center to enable academic and biopharma researchers to conduct large-scale human genome studies, closed a $39M Series E financing. Participants include Sands Capital Management, Essex Woodlands, OVP Venture Partners, Prospect Venture Partners, OrbiMed Advisors, Highland Capital Management and Enterprise Partners.

Poxel, SA: Series A $20.3M

arubenstein — Fri, 27 Aug 2010 05:26:25 +0000

Poxel (France) a clinical-stage small molecule company focused on Type-2 diabetes and metabolic disease, closed a $20.3M Series A financing. Participants include Edmond de Rothschild Investment Partners, InnoBio Ventures and Crédit Agricole Private Equity.

Gemin X Pharmaceuticals, Inc.: Series E $8M

arubenstein — Tue, 24 Aug 2010 04:28:24 +0000

Gemin X Pharmaceuticals (Malvern, PA) a clinical-stage biopharmaceutical company focused on chronic lymphocytic leukemia, melanoma, small cell lung cancer, lymphoma, myeloma and glioblastoma multiforme, closed a $8M Series E financing. Participants include Caxton Advantage Life Sciences Fund and Sanderling Ventures.

Health Market Science, Inc.: Series B $6.1M

arubenstein — Mon, 23 Aug 2010 03:32:42 +0000

Health Market Science (King of Prussia, PA) a commercial-stage biopharma and healthcare data and analytics provider, closed a $6.1M Series B financing. Participants include Cross Atlantic Capital Partners and Edison Venture Fund.

Great Lakes Pharmaceuticals, Inc.: Series B $3.1M

arubenstein — Mon, 23 Aug 2010 03:26:37 +0000

Great Lakes Pharmaceuticals (Cleveland, OH) a clinical-stage drug:device company focused on catheter-related bloodstream infection, closed a $3.1M Series B financing. Participants include Charter Life Sciences, Early Stage Partners, Ohio Tech Angels and North Coast Angel Fund.

Solazyme, Inc.: Series D $52M

arubenstein — Fri, 20 Aug 2010 06:22:57 +0000

Solazyme (San Francisco, CA) a development-stage synthetic biology company focused on algal biodiesel and industrial chemicals, closed a $52M Series D financing. Participants include Morgan Stanley Venture Partners, Braemar Energy Ventures, Lightspeed Venture Partners, Roda Group, Harris and Harris Group, VantagePoint Venture Partners, Zygote Ventures, Chevron Technology Venture Investments and San-Ei Gen.